Vapotherm, Inc. (VAPO): Price and Financial Metrics
GET POWR RATINGS... FREE!
VAPO POWR Grades
- Sentiment is the dimension where VAPO ranks best; there it ranks ahead of 60% of US stocks.
- The strongest trend for VAPO is in Stability, which has been heading up over the past 51 weeks.
- VAPO ranks lowest in Quality; there it ranks in the 4th percentile.
VAPO Stock Summary
- Vapotherm Inc's stock had its IPO on November 14, 2018, making it an older stock than only 7.42% of US equities in our set.
- The ratio of debt to operating expenses for Vapotherm Inc is higher than it is for about 26.07% of US stocks.
- As for revenue growth, note that VAPO's revenue has grown 59.31% over the past 12 months; that beats the revenue growth of 89.18% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Vapotherm Inc are PWFL, ESTA, ATRI, AXGN, and CSII.
- VAPO's SEC filings can be seen here. And to visit Vapotherm Inc's official web site, go to www.vapotherm.com.
VAPO Valuation Summary
- VAPO's price/earnings ratio is -12.5; this is 134.25% lower than that of the median Healthcare stock.
- Over the past 34 months, VAPO's EV/EBIT ratio has gone down 4.7.
- Over the past 34 months, VAPO's EV/EBIT ratio has gone down 4.7.
Below are key valuation metrics over time for VAPO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VAPO | 2021-08-31 | 5.8 | 7.7 | -12.5 | -12.6 |
| VAPO | 2021-08-30 | 5.9 | 7.8 | -12.7 | -12.8 |
| VAPO | 2021-08-27 | 5.7 | 7.6 | -12.4 | -12.5 |
| VAPO | 2021-08-26 | 5.7 | 7.7 | -12.5 | -12.5 |
| VAPO | 2021-08-25 | 5.4 | 7.3 | -11.8 | -11.9 |
| VAPO | 2021-08-24 | 5.5 | 7.3 | -11.9 | -12.0 |
VAPO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VAPO has a Quality Grade of F, ranking ahead of 4.21% of graded US stocks.
- VAPO's asset turnover comes in at 0.636 -- ranking 62nd of 184 Medical Equipment stocks.
- 500 - Internal server error
The table below shows VAPO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.636 | 0.505 | -0.633 |
| 2021-03-31 | 0.680 | 0.511 | -0.536 |
| 2020-12-31 | 0.688 | 0.501 | -0.623 |
| 2020-09-30 | 0.624 | 0.493 | -0.583 |
| 2020-06-30 | 0.572 | 0.480 | -0.610 |
| 2020-03-31 | 0.521 | 0.462 | -0.703 |
VAPO Stock Price Chart Interactive Chart >
VAPO Price/Volume Stats
| Current price | $20.90 | 52-week high | $38.46 |
| Prev. close | $20.78 | 52-week low | $16.64 |
| Day low | $20.63 | Volume | 111,200 |
| Day high | $21.29 | Avg. volume | 260,320 |
| 50-day MA | $25.39 | Dividend yield | N/A |
| 200-day MA | $24.96 | Market Cap | 543.55M |
Vapotherm, Inc. (VAPO) Company Bio
Vapotherm Inc. Vapotherm, Inc. is a global medical technology company. The Company is focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products that are used to treat patients suffering from respiratory distress. Its Hi-VNI technology delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Its Precision Flow systems uses its Hi-VNI technology. It offers three versions of its Precision Flow systems: Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow versions are integrated systems that provide precise user control of temperature, air flow and percentage oxygen through a one-button interface.
Latest VAPO News From Around the Web
Below are the latest news stories about Vapotherm Inc that investors may wish to consider to help them evaluate VAPO as an investment opportunity.
Shareholders in Vapotherm (NYSE:VAPO) have lost 14%, as stock drops 15% this past weekThe simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that... |
Vapotherm Stock: Can HVT 2.0 Lead to Gains?I am neutral on Vapotherm (VAPO), as its attractive stock price and high potential pipeline make it look attractive. However, the company has a lot of risk stemming from its declining revenues and widening losses. Vapotherm is a publicly held corporation that manufactures advanced respiratory technology for ventilator support. The company is known for developing the first non-invasive, humidified high-velocity therapy nasal cannula system for patients suffering from respiratory distress, who cannot tolerate breathing masks. Strengths Vapotherm recently announced it has received 510(k) clearance from the FDA for its innovative next-generation system, the HVT 2.0. This particular system is designed to provide high flow therapy using an integrated air source. |
Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production CapacityEXETER, N.H., September 08, 2021--Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity. The expansion of disposables production capacity will include the addition of assembly lines in Mexico which will increase capacity by 75% without adding material fixed costs and prepare the Company for the possibility that COVID-19 becomes a permanent part of the respiratory landsc |
Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation PlatformEXETER, N.H., August 30, 2021--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This next generation system is designed to provide high velocity therapy using an integrated air source, eliminating the need for wall air or any pressurized air source. It is estimated that 50% of U.S. hospital beds don’t have wall air. When paired with an oxygen source, the HVT 2.0 will support patien |
Vapotherm (VAPO) Reports Q2 Loss, Tops Revenue EstimatesVapotherm (VAPO) delivered earnings and revenue surprises of -4.69% and 13.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
VAPO Price Returns
| 1-mo | -26.62% |
| 3-mo | -4.08% |
| 6-mo | -1.88% |
| 1-year | -29.63% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -22.19% |
| 2020 | 120.89% |
| 2019 | -39.05% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...